CD20抗体の世界市場レポート 2025年

CD20抗体市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.2％で162億4,000万米ドルに成長します。予測期間における成長の背景には、先進的ながん免疫療法に対する需要の高まり、自己免疫疾患の有病率の増加、バイオシミラーCD20抗体の採用拡大、併用療法への応用拡大、バイオ医薬品研究への投資の増加、個別化医療に対する意識の高まりなどがあります。主な動向としては、次世代CD20抗体の開発、抗体薬物複合体の発展、抗体設計における人工知能の統合、二重特異性抗体技術の向上、CD20を標的とするCAR-T細胞療法の台頭、デリバリー強化のためのナノテクノロジーの採用、ハイスループットスクリーニング法の進歩などが挙げられます。

B細胞性悪性腫瘍の有病率の増加は、今後数年間のCD20抗体市場の拡大を牽引すると予想されます。B細胞悪性腫瘍とは、免疫反応に重要な白血球の一種であるB細胞に影響を及ぼすがんの発生率の増加を指します。この増加には、高齢化、遺伝的素因、環境暴露、ライフスタイルの変化、検出方法の進歩、免疫系の変化など、さまざまな要因が関与しています。リツキシマブなどのCD20抗体は、非ホジキンリンパ腫や慢性リンパ性白血病などの悪性B細胞を標的として排除し、治療成績を改善する上で重要な役割を果たしています。例えば、米国を拠点とする非営利の医学団体である米国心臓病学会の2024年の報告書によると、2025年には、成人・小児を含めて約8万350人（男性4万5,140人、女性3万5,210人）が非ホジキンリンパ腫（NHL）と診断されると推定されています。さらに、約1万9,390人（男性1万1,060人、女性8,330人）がこのがんで死亡すると予測されています。その結果、B細胞性悪性腫瘍の発生が増加しており、CD20抗体市場の拡大を後押ししています。

CD20抗体市場の主要企業は、治療へのアクセスを改善し、ヘルスケアコストを削減し、B細胞悪性腫瘍や自己免疫疾患に対する手頃で効果的な治療に対するニーズの高まりに対応するため、バイオシミラーなどの技術的進歩を優先しています。バイオシミラーとは、安全性、純度、有効性に大きな違いがなく、すでに承認されている基準製剤に酷似した生物学的製剤のことです。例えば、2024年7月、インドの製薬会社ドクター・レディーズ・ラボラトリーズは、リツキシマブのバイオシミラー候補について、米国食品医薬品局（USFDA）から審査完了通知（CRL）を受領したと発表しました。同社は、米国食品医薬品局（USFDA）と協力し、指定された期間内にすべての懸念事項を解決し、バイオシミラーリツキシマブを米国の患者に導入することを目指します。リツキシマブ・バイオシミラーは、B細胞表面のCD20タンパク質を標的とし、異常または活動しすぎのB細胞を破壊する反応を引き起こすことにより機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界CD20抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のCD20抗体市場：成長率分析
• 世界のCD20抗体市場の実績：規模と成長, 2019-2024
• 世界のCD20抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界CD20抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のCD20抗体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• 世界のCD20抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フローサイトメトリー
• 酵素免疫測定（ELISA）
• ウェスタンブロット
• 免疫沈降法
• 免疫蛍光法
• 世界のCD20抗体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界のCD20抗体市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リツキシマブ
• オビヌツズマブ
• オファツムマブ
• 世界のCD20抗体市場、ポリクローナル抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のポリクローナル抗体
• ヒトポリクローナル抗体
• 組み換えポリクローナル抗体

第7章 地域別・国別分析

• 世界のCD20抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のCD20抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• CD20抗体市場：競合情勢
• CD20抗体市場：企業プロファイル
  • F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Biogen Inc
• Genentech Inc
• Bio-Rad Laboratories Inc
• Genmab A/S
• Bio-Techne
• LFB Biotechnologies SA
• Abcam Limited
• Sino Biological Inc
• Mylan NV
• Immunomedics Inc
• Spectrum Pharmaceuticals Inc
• MyBiosource Inc
• IGM Biosciences Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• CD20抗体市場2029：新たな機会を提供する国
• CD20抗体市場2029：新たな機会を提供するセグメント
• CD20抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

CD20 antibodies are monoclonal antibodies that specifically target CD20, a protein present on the surface of B cells, a type of white blood cell involved in the immune response. These antibodies are primarily used to treat conditions associated with abnormal B-cell function, including cancers and autoimmune diseases. Their primary role is to bind to the CD20 protein on B cells and initiate their destruction.

The primary end users of CD20 antibodies include hospitals, specialty clinics, ambulatory surgical centers, and others. These antibodies are utilized in various applications such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, and immunofluorescence. CD20 antibodies are categorized into two main types, monoclonal and polyclonal antibodies. Monoclonal antibodies are laboratory-engineered proteins designed to bind to specific targets, such as the CD19 antigen found on B cells.

The CD-20 antibody market research report is one of a series of new reports from The Business Research Company that provides CD-20 antibody market statistics, including CD-20 antibody industry global market size, regional shares, competitors with a CD-20 antibody market share, detailed CD-20 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the CD-20 antibody industry. This CD-20 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CD20 antibody market size has grown rapidly in recent years. It will grow from $9.94 billion in 2024 to $10.99 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the rising incidence of autoimmune diseases, the growing demand for targeted therapies, the increasing approvals of biosimilars, rising healthcare expenditure, improvements in healthcare infrastructure, and greater awareness of the benefits of immunotherapy.

The CD20 antibody market size is expected to see rapid growth in the next few years. It will grow to $16.24 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the rising demand for advanced cancer immunotherapies, the increasing prevalence of autoimmune disorders, the growing adoption of biosimilar CD20 antibodies, the expanding applications in combination therapies, the increasing investment in biopharmaceutical research, and the growing awareness of personalized medicine. Key trends include the development of next-generation CD20 antibodies, advancements in antibody-drug conjugates, the integration of artificial intelligence in antibody design, improvements in bispecific antibody technology, the rise of CAR-T cell therapies targeting CD20, the adoption of nanotechnology for enhanced delivery, and advancements in high-throughput screening methods.

The growing prevalence of B-cell malignancies is anticipated to drive the expansion of the CD20 antibody market in the coming years. B-cell malignancies refer to the increasing incidence of cancers affecting B cells, a type of white blood cell crucial to the immune response. Various factors contribute to this rise, including an aging population, genetic predispositions, environmental exposures, lifestyle changes, advancements in detection methods, and alterations in the immune system. CD20 antibodies, such as rituximab, play a critical role in targeting and eliminating malignant B-cells in conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby improving treatment outcomes. For instance, a 2024 report by the American College of Cardiology, a US-based nonprofit medical association, estimates that in 2025, approximately 80,350 individuals (45,140 males and 35,210 females), including both adults and children, will be diagnosed with non-Hodgkin lymphoma (NHL). Furthermore, around 19,390 people (11,060 males and 8,330 females) are projected to succumb to this cancer. As a result, the increasing occurrence of B-cell malignancies is propelling the expansion of the CD20 antibody market.

Leading companies in the CD20 antibody market are prioritizing technological advancements such as biosimilars to improve treatment accessibility, lower healthcare costs, and meet the growing need for affordable and effective therapies for B-cell malignancies and autoimmune diseases. Biosimilars are biologic medical products that closely resemble an already approved reference product without any significant differences in safety, purity, or efficacy. For example, in July 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate. The company intends to collaborate with the USFDA to resolve all concerns within the designated timeframe, aiming to introduce the biosimilar rituximab to patients in the United States. Rituximab biosimilar functions by targeting the CD20 protein on the surface of B-cells, triggering a response that leads to the destruction of these abnormal or overactive B-cells.

In October 2024, GSK plc, a UK-based biopharmaceutical and biotechnology company, acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager (TCE) currently in clinical development, from Chimagen Biosciences for an undisclosed sum. Through this acquisition, GSK aims to develop and commercialize CMG1A46, focusing on B cell-driven autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with the potential for expansion into related autoimmune conditions. Chimagen Biosciences, a China-based clinical-stage biotechnology firm, specializes in discovering and developing novel multi-specific T cell-engagers and NK cell-engagers.

Major players in the CD20 antibody market are F Hoffmann-La Roche AG, Merck & Co Inc, Thermo Fisher Scientific Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Genentech Inc, Bio-Rad Laboratories Inc, Genmab A/S, Bio-Techne, LFB Biotechnologies SA, Abcam Limited, Sino Biological Inc, Mylan NV, Immunomedics Inc, Spectrum Pharmaceuticals Inc, MyBiosource Inc, IGM Biosciences Inc, and TG Therapeutics Inc.

North America was the largest region in the CD20 antibody market in 2024. The regions covered in CD20 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD20 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CD20 antibody market consists of sales of rituximab, obinutuzumab, and ofatumumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CD20 Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cd20 antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cd20 antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cd20 antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibody; Polyclonal Antibody
• 2) By Application: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Western Blot; Immunoprecipitation; Immunofluorescence
• 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Monoclonal Antibody: Rituximab; Obinutuzumab; Ofatumumab
• 2) By Polyclonal Antibody: Conventional Polyclonal Antibodies; Human Polyclonal Antibodies; Recombinant Polyclonal Antibodies
• Companies Mentioned: F Hoffmann-La Roche AG; Merck & Co Inc; Thermo Fisher Scientific Inc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. CD20 Antibody Market Characteristics

3. CD20 Antibody Market Trends And Strategies

4. CD20 Antibody Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global CD20 Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global CD20 Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global CD20 Antibody Market Growth Rate Analysis
• 5.4. Global CD20 Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global CD20 Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global CD20 Antibody Total Addressable Market (TAM)

6. CD20 Antibody Market Segmentation

• 6.1. Global CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• Polyclonal Antibody
• 6.2. Global CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flow Cytometry
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Western Blot
• Immunoprecipitation
• Immunofluorescence
• 6.3. Global CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global CD20 Antibody Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab
• Obinutuzumab
• Ofatumumab
• 6.5. Global CD20 Antibody Market, Sub-Segmentation Of Polyclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Polyclonal Antibodies
• Human Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

7. CD20 Antibody Market Regional And Country Analysis

• 7.1. Global CD20 Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global CD20 Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific CD20 Antibody Market

• 8.1. Asia-Pacific CD20 Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China CD20 Antibody Market

• 9.1. China CD20 Antibody Market Overview
• 9.2. China CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India CD20 Antibody Market

• 10.1. India CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan CD20 Antibody Market

• 11.1. Japan CD20 Antibody Market Overview
• 11.2. Japan CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia CD20 Antibody Market

• 12.1. Australia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia CD20 Antibody Market

• 13.1. Indonesia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea CD20 Antibody Market

• 14.1. South Korea CD20 Antibody Market Overview
• 14.2. South Korea CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe CD20 Antibody Market

• 15.1. Western Europe CD20 Antibody Market Overview
• 15.2. Western Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK CD20 Antibody Market

• 16.1. UK CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany CD20 Antibody Market

• 17.1. Germany CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France CD20 Antibody Market

• 18.1. France CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy CD20 Antibody Market

• 19.1. Italy CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain CD20 Antibody Market

• 20.1. Spain CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe CD20 Antibody Market

• 21.1. Eastern Europe CD20 Antibody Market Overview
• 21.2. Eastern Europe CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia CD20 Antibody Market

• 22.1. Russia CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America CD20 Antibody Market

• 23.1. North America CD20 Antibody Market Overview
• 23.2. North America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA CD20 Antibody Market

• 24.1. USA CD20 Antibody Market Overview
• 24.2. USA CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada CD20 Antibody Market

• 25.1. Canada CD20 Antibody Market Overview
• 25.2. Canada CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America CD20 Antibody Market

• 26.1. South America CD20 Antibody Market Overview
• 26.2. South America CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil CD20 Antibody Market

• 27.1. Brazil CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East CD20 Antibody Market

• 28.1. Middle East CD20 Antibody Market Overview
• 28.2. Middle East CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa CD20 Antibody Market

• 29.1. Africa CD20 Antibody Market Overview
• 29.2. Africa CD20 Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa CD20 Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa CD20 Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. CD20 Antibody Market Competitive Landscape And Company Profiles

• 30.1. CD20 Antibody Market Competitive Landscape
• 30.2. CD20 Antibody Market Company Profiles
  • 30.2.1. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. CD20 Antibody Market Other Major And Innovative Companies

• 31.1. Amgen Inc
• 31.2. Teva Pharmaceutical Industries Ltd
• 31.3. Biogen Inc
• 31.4. Genentech Inc
• 31.5. Bio-Rad Laboratories Inc
• 31.6. Genmab A/S
• 31.7. Bio-Techne
• 31.8. LFB Biotechnologies SA
• 31.9. Abcam Limited
• 31.10. Sino Biological Inc
• 31.11. Mylan NV
• 31.12. Immunomedics Inc
• 31.13. Spectrum Pharmaceuticals Inc
• 31.14. MyBiosource Inc
• 31.15. IGM Biosciences Inc

32. Global CD20 Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CD20 Antibody Market

34. Recent Developments In The CD20 Antibody Market

35. CD20 Antibody Market High Potential Countries, Segments and Strategies

• 35.1 CD20 Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 CD20 Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 CD20 Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer